Ensayos clínicos de Linfoma en Ohio
28 estudios sobre Linfoma buscan participantes en Ohio.
Ciudades en Ohio
Texto oficial del estudio (inglés)
Epco, Zanu, Ritux for R/R FL or MZL
- The Ohio State University Wexner Medical Center, Columbus
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06563596Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
- Cincinnati Children's Hospital Medical Center, Cincinnati
ReclutandoFase 1
24 Months – 18 Years · Todos los sexos · Actualizado el 25 sept 2026 · NCT06441331A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
- Cleveland Clinic, Cleveland
- The Ohio State University Comprehensive Cancer Center, Columbus
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 23 sept 2026 · NCT07015242Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
- Ohio State University Comprehensive Cancer Center, Columbus
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 23 sept 2026 · NCT04301076A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- University of Cincinnati, Cincinnati
- The Cleveland Clinic Foundation, Cleveland
- The Ohio State University, Columbus
- y 1 más
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 17 sept 2026 · NCT07221500Collection of Tissue Samples for Cancer Research
- Ohio State University, Columbus
ReclutandoEstudio observacional
2 Months · Todos los sexos · Actualizado el 16 sept 2026 · NCT00900198CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- Cincinnati Children's Hospital Medical Center, Cincinnati
ReclutandoFase 1/2
12 Months – 21 Years · Todos los sexos · Actualizado el 11 sept 2026 · NCT04870944Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
- Research Site, Cleveland
ReclutandoFase 3
Edades de 18 a 18 · Todos los sexos · Actualizado el 8 sept 2026 · NCT07509151A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
- University Hospitals Cleveland Medical Center, Cleveland
ReclutandoFase 2
1 Month – 17 Years · Todos los sexos · Actualizado el 1 sept 2026 · NCT04570423Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- University of Cincinnati (UC) Physicians Company, LLC, Cincinnati
- Cleveland Clinic, Cleveland
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 ago 2026 · NCT05826535A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
- University Hospitals Cleveland Medical Center, Cleveland
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 21 ago 2026 · NCT07192471A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
- Cleveland Clinic, Cleveland
ReclutandoFase 1/2
Edades de 12 en adelante · Todos los sexos · Actualizado el 20 ago 2026 · NCT06678659A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
- University of Cincinnatti Medical Center, Cincinnatti
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 17 ago 2026 · NCT06528301Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- The Ohio State University Wexner Medical Center, Columbus
ReclutandoFase 1/2
Edades de 13 a 90 · Todos los sexos · Actualizado el 6 ago 2026 · NCT06533579A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Oncology Hematology Care Clinical Trials, Cincinnati
- University of Cincinnati, Cincinnati
- Cleveland Clinical Taussig Cancer Center, Cleveland
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 ago 2026 · NCT07188558DALY II USA/ MB-CART2019.1 for DLBCL
- The Ohio State University Wexner Medical Center James Cancer, Columbus
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 13 jul 2026 · NCT04792489A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)
- University Hospitals Cleveland Medical Center, Cleveland
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 8 jul 2026 · NCT07465835A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- University of Cincinnati Medical Center, Cincinnati
- Cleveland Clinic, Cleveland
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 2 jul 2026 · NCT05131022A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
- Dren Investigational Site, Columbus
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 17 jun 2026 · NCT05475925Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Cincinnati Children's Hospital Medical Center, Cincinnati
ReclutandoEstudio observacional
Edades de 0 a 38 · Todos los sexos · Actualizado el 4 jun 2026 · NCT06131801Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Children's Hospital Medical Center of Akron, Akron
- Cincinnati Children's Hospital Medical Center, Cincinnati
ReclutandoEstudio observacional
Todas las edades · Todos los sexos · Actualizado el 18 may 2026 · NCT01790152Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies
- The Ohio State University, Columbus
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 24 abr 2026 · NCT06801002CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Cleveland Clinic, Cleveland
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 16 abr 2026 · NCT03328078Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
- Ohio State University Comprehensive Cancer Center, Columbus
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 15 abr 2026 · NCT07356245The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- Gabrail Cancer Center Research,, Canton
ReclutandoFase 1/2
Edades de 12 a 95 · Todos los sexos · Actualizado el 15 abr 2026 · NCT04329728cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Cleveland Clinic, Cleveland
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
Edades de 40 en adelante · Todos los sexos · Actualizado el 20 ene 2026 · NCT05366881Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
- Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 nov 2025 · NCT06916767HPC Offered for PRESERVE Expansion
- The Ohio State University Medical Center, Columbus
ReclutandoEstudio observacional
Edades de 12 a 80 · Todos los sexos · Actualizado el 28 ago 2025 · NCT07145411De ClinicalTrials.gov, datos obtenidos el 30 sept 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.